The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor (ROR) pathways in cancer and...
Clinical efficacy and safety data will be presented from over 70 small-cell lung cancer (SCLC) patients in Hengrui's ongoing, multi-site, open label Phase 1...
SHANGHAI, July 21, 2025 /PRNewswire/ -- DualityBio (HKEX Stock Code: 9606.HK) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track...
SAN FRANCISCO and SUZHOU, China, July 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality...
USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, July 10, 2025 /PRNewswire/ -- USA News Group News Commentary – Cancer rates are...
USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, July 10, 2025 /PRNewswire/ -- USA News Group News Commentary – Cancer rates are...
Orphan drug designation highlights the potential for ADRX-0405 to address the high unmet need in gastric cancerSAN DIEGO, July 8, 2025 /PRNewswire/ -- Adcentrx Therapeutics ("Adcentrx"),...
CHENNAI, India, July 4, 2025 /PRNewswire/ -- India's mining and construction equipment sector is poised for significant growth, projected to expand from $16 billion...
München, Deutschland, 04. Juli 2025 – Das Komitee des Strüngmann Award gab heute bekannt, dass Dr. Dragan Grabulovski, Dr. Philipp Spycher und Dr. Isabella Attinger-Toller, die Gründer von Araris Biotech, als die diesjährigen Preisträger ausgezeichnet wurden. Der Award verfolgt das Ziel, herausragende unternehmerische und wissenschaftliche Leistungen sowie bahnbrechende Ideen in der Life-Science-Branche zu fördern. Das Gründerteam von Araris Biotech überzeugte nicht nur durch die Entwicklung einer neuartigen Technologie im Bereich der Antikörper-Wirkstoff-Konjugate, sondern auch durch deren erfolgreiche Validierung in Form von Partnerschaften und einem präklinischen Exit. Diese neue Medikamentenklasse hat das Potenzial, maßgeblich zur Weiterentwicklung zielgerichteter Krebstherapien beizutragen und somit einen Mehrwert für Menschen mit Krebserkrankungen weltweit zu erreichen.
Munich, Germany, July 04, 2025 – The Strüngmann Award selection committee today announced that Dragan Grabulovski, Ph.D., Philipp Spycher, Ph.D., and Isabella Attinger-Toller, Ph.D., the founders of Araris Biotech, have been honored as this year’s winners. The award aims to support outstanding entrepreneurial and scientific achievements, as well as ground-breaking ideas in the life sciences industry. Araris Biotech’s founding team distinguished itself not only by developing of a novel technology in the antibody-drug conjugates (ADCs) field, but also by successfully validating this innovation through partnerships and a preclinical exit. This new drug class has the potential to significantly advance the development of targeted cancer therapies, thereby delivering added value for people living with cancer worldwide.
BRATISLAVA, Slovakia, July 02, 2025 (GLOBE NEWSWIRE) -- ESET Research has released a white paper about Gamaredon’s updated cyberespionage toolset, new stealth-focused techniques, and aggressive spearphishing operations observed across the previous year. Gamaredon, attributed by the Security Service of Ukraine (SSU) to the 18th Center of Information Security of Russia’s Federal Security Service (FSB), has targeted Ukrainian governmental institutions since at least 2013. In 2024, Gamaredon exclusively attacked Ukrainian institutions. ESET’s latest research shows that the group remains highly active, consistently targeting Ukraine, but has notably adapted its tactics and tools. The group’s objective is cyberespionage aligned with Russian geopolitical interests. Last year, the group significantly increased the scale and frequency of spearphishing campaigns, employing new delivery methods, and one attack payload was used solely to spread Russian propaganda.